Table 1. Participant Characteristics at Randomization.

	MBSR (n = 20) ¹	PCT (n = 10)	P value^a
Age in years, median (range)	47 (21-65)	53.5 (29-59)	0.07
Female n (%)	15 (75)	7 (70)	0.77
Race n (%)
White	20 (100)	9 (90)	0.33
Black/African American	0 (0)	1 (10)
Hispanic/Latino n (%)	1 (5)	1 (10)	0.56
Married n (%)	11 (55)	8 (80)	0.18
College degree n (%)	18 (90)	6 (60)	0.14
Employment n (%)
Full-time or part-time	12 (75)	9(90)	0.63
Other (retired, homemaker, student, etc.)	5 (25)	1 (10)
No. of medical co-morbidities^b n (%)
None	5 (25)	2 (20)	0.72
1	4 (20)	5 (50)
≥ 2	11 (55)	3 (30)
Insomnia duration in years, median (range)	5 (1-22)	9 (1-30)	0.16
Taking medication for sleep at start of screening n (%)	15 (75)	5 (56) ^c	0.40
Prior use of eszopiclone (LUNESTA™)n (%)	4 (20)	2 (20)	0.69
History of depression or anxiety disorder (diagnosed) n (%)	9(47)	1 (10)	0.046
Current use of medication for depression n (%)	3 (16) ^c	0 (0)	0.53

Abbreviations: MBSR, Mindfulness-based Stress Reduction; PCT, Pharmacotherapy

P values from Fisher's Exact test or Mann-Whitney U test

Medical co-morbidities were recorded as pulmonary, cardiovascular, neurologic, gastrointestinal, endocrine, renal, hematologic, cancer, musculoskeletal or pain, or head, eyes, ears or throat.

One unknown